Establishment of a continuous somatostatin-producing line of medullary thyroid carcinoma cells from BALB/c mice

Tischler, Arthur S.; Lee, Y. C.; Costopoulos, Donna; Nunnemacher, G; DeLellis, Ronald A.; Zwieten, Matthew J. van; Wolfe, Hubert J.; Bloom, S R

doi:10.1677/joe.0.1100309

Cited by 8 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations suggest that production of somatostatin is not a facultative property of many C-cells but that during neonatal life C-cells differentiate into two types, one producing calcitonin but not somatostatin and the other producing both hormones. The description of the production of an autonomous somatostatin-producing cell line from a mouse medullary carcinoma supports this (18).…”

Section: Immunocytochemistrysupporting

confidence: 64%

Synthesis and storage in rat thyroid C-cells.

Thomas

Neonakis²,

Davies³

et al. 1994

J Histochem Cytochem.

View full text Add to dashboard Cite

Thyroid C-cells have the capacity to produce a variety of peptides, as do C-cell tumors. The cellular content of one such peptide, somatostatin, is restricted to a minority of C-cells in rat and human. We set out to clarify whether the synthesis of somatostatin is equally restricted and to study changes that occur in somatostatin synthesis with age. We used immunocytochemistry to localize somatostatin and calcitonin in conjunction with in situ hybridization, using digoxigeninlabeled oligoprobes to localize somatostatin and calcitonon calcitonin, and somatostatin synthesis, as shown by mRNA content, is limited to the subset of cells containing immunoreactive somatostatin. The numbem of C-cells in general and of the subset synthesizing somatostatin increase between juvenile and adult animals, but the somatostatin cells remain confined to a small area of the gland. These findings support the proposal that somatostatin production is not facultative, but that C-cells differentiate into two distinct sub- "As

show abstract

Section: Immunocytochemistrysupporting

confidence: 64%

Synthesis and storage in rat thyroid C-cells.

Thomas

Neonakis²,

Davies³

et al. 1994

J Histochem Cytochem.

View full text Add to dashboard Cite

show abstract

“…Cells from aggressive fibromatosis tumors or hypertrophic wounds treated with Nefopam had a significantly lower proliferation rate, while normal fibroblasts from the same patients did not demonstrate an appreciable change in proliferation rate, as measured using the BrdU incorporation assay [22] (Fig. 2A).…”

Section: Resultsmentioning

confidence: 94%

A High Throughput Screen Identifies Nefopam as Targeting Cell Proliferation in β-Catenin Driven Neoplastic and Reactive Fibroproliferative Disorders

et al. 2012

View full text Add to dashboard Cite

Fibroproliferative disorders include neoplastic and reactive processes (e.g. desmoid tumor and hypertrophic scars). They are characterized by activation of β-catenin signaling, and effective pharmacologic approaches are lacking. Here we undertook a high throughput screen using human desmoid tumor cell cultures to identify agents that would inhibit cell viability in tumor cells but not normal fibroblasts. Agents were then tested in additional cell cultures for an effect on cell proliferation, apoptosis, and β-catenin protein level. Ultimately they were tested in Apc1638N mice, which develop desmoid tumors, as well as in wild type mice subjected to full thickness skin wounds. The screen identified Neofopam, as an agent that inhibited cell numbers to 42% of baseline in cell cultures from β-catenin driven fibroproliferative disorders. Nefopam decreased cell proliferation and β-catenin protein level to 50% of baseline in these same cell cultures. The half maximal effective concentration in-vitro was 0.5 uM and there was a plateau in the effect after 48 hours of treatment. Nefopam caused a 45% decline in tumor number, 33% decline in tumor volume, and a 40% decline in scar size when tested in mice. There was also a 50% decline in β-catenin level in-vivo. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo, and may be an effective therapy for neoplastic and reactive processes driven by β-catenin mediated signaling.

show abstract

“…This change may require morphometry for definitive diagnosis (Bosland andBär, 1984 andTischler et al, 1985) and is not accompanied by cytological atypia. Diffuse hyperplasia may expand the medullary region with compression of the surrounding cortical tissue.…”

Section: Classificationmentioning

confidence: 99%

“…Several studies suggest that the development of adrenal medullary hyperplasia and pheochromocytomas in rats is accompanied by increasing NE/E ratios (Bär, 1988;Bosland and Bär, 1984;Eränkö , 1955;Ribelin et al, 1984 andTischler et al, 1985). Rat pheochromocytomas appear, in most instances, to have a distinctive phenotype characterized by predominant or exclusive production of NE and by secretory granules smaller and sparser than those in typical E and NE cells (Figure 8) (Tischler et al,Figure 7 Rat adrenal gland with 'malignant' pheochromocytoma.…”

Section: Functionmentioning

confidence: 99%

“…Rat pheochromocytomas appear, in most instances, to have a distinctive phenotype characterized by predominant or exclusive production of NE and by secretory granules smaller and sparser than those in typical E and NE cells (Figure 8) (Tischler et al,Figure 7 Rat adrenal gland with 'malignant' pheochromocytoma. (Tischler et al, 1985). In the bottom panels, adjacent sections are stained immunohistochemically for tyrosine hydroxylase (TH), dopamine-b-hydroxylase (DBH), phenylethanolamine-N-transferase (PNMT), and chromogranin A (CgA).…”

Section: Functionmentioning

confidence: 99%

See 1 more Smart Citation